Phase 2Completed

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)

Sponsor
OPKO Health, Inc. (Industry)
Enrollment
171 enrolled
Conditions
COVID-19; Coronavirus; SARS-CoV2 Infection
Interventions
Rayaldee; Placebo
Ages
adults, older adults
Registry
NCT04551911

Full record on ClinicalTrials.gov

From the registry

This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.

Primary outcomes

  • Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).
  • Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered